Opthea Developing Therapy for Eye Diseases

Opthea is a public Australian biotechnology company (ASX:OPT) developing a novel biologic therapy, OPT-302, for the treatment of eye diseases.

OPT-302, blocks two members of the vascular endothelial growth factor family, namely VEGF-C and   VEGF-D, which cause blood vessels to grow and leak. Aberrant blood vessel growth and vascular leakage are hallmarks of several eye diseases including wet age-related macular degeneration (wet AMD) and diabetic macular edema (DME).

Opthea has completed a Phase 1/2a clinical trial in the US investigating OPT-302 in wet AMD patients. 

Opthea is currently enrolling patients in a Phase 2b clinical trial for patients with wet AMD and a Phase 1b/2a clinical trial in patients with DME.  

Latest News

03 JAN 2018. “Opthea Initiates OPT-302 Diabetic Macular Edema Trial"

read more >>

19 DEC 2017. “Opthea Doses First Patient in OPT-302 wAMD Ph2b trial"

read more >>

15 AUG 2017. “Opthea Presents Further Positive Data from the OPT-302 Ph1/2A clinical trial"

read more >>

11 AUG 2017. “Opthea presents at the 2017 Ophthalmology Innovation Summit in Boston"

read more >>
Share Price